INBX
Inhibrx Biosciences, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.49B
P/E Ratio
—
EPS
$-8.39
Beta
—
52W High
$155.29
52W Low
$12.68
50-Day MA
$93.73
200-Day MA
$68.70
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Inhibrx Biosciences, Inc.
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla, California.
Fundamentals
| Revenue (TTM) | $1.30M |
| Gross Profit (TTM) | $-100.07M |
| EBITDA | $-120.71M |
| Operating Margin | -9465.00% |
| Return on Equity | -354.70% |
| Return on Assets | -36.10% |
| Revenue/Share (TTM) | $0.08 |
| Book Value | $0.55 |
| Price-to-Book | 212.28 |
| Price-to-Sales (TTM) | 1143.45 |
| EV/Revenue | 1158.02 |
| EV/EBITDA | 0.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $14.67M |
| Float | $7.86M |
| % Insiders | 23.16% |
| % Institutions | 82.93% |
Historical Volatility
HV 10-Day
107.84%
HV 20-Day
105.15%
HV 30-Day
133.03%
HV 60-Day
110.52%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($277.50 target)
1
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026